aVaxziPen is focusing on next-generation vaccines for infectious diseases and emerging threat pathogens.
aVaxziPen has raised $1.6M in total funding. The most recent round was Undisclosed. The last funding was announced in June 2023.
aVaxziPen's investors include Coalition for Epidemic Preparedness Innovations.
aVaxziPen is headquartered in Abingdon, United Kingdom.
aVaxziPen is focusing on next-generation vaccines for infectious diseases and emerging threat pathogens.
aVaxziPen is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"aVaxziPen — Funding & Investors." VCBacked, June 6, 2023, https://www.vcbacked.co/company/avaxzipen. Accessed November 13, 2026.
VCBacked. (2023). aVaxziPen — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/avaxzipen
{{cite web |title=aVaxziPen — Funding & Investors |url=https://www.vcbacked.co/company/avaxzipen |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at aVaxziPen? Request a listing update